{
    "clinical_study": {
        "@rank": "8045", 
        "acronym": "GO-EASY", 
        "arm_group": {
            "arm_group_label": "Golimumab 50 mg", 
            "arm_group_type": "Experimental", 
            "description": "Golimumab dosed subcutaneously at a dose of 50 mg once monthly for up to 12 months."
        }, 
        "brief_summary": {
            "textblock": "The objective of this study is to determine the difference in the annual incidence rate of\n      uveitis attacks in participants with ankylosing spondylitis (AS) before treatment and after\n      the start of treatment with golimumab."
        }, 
        "brief_title": "The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012)", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Ankylosing Spondylitis", 
        "condition_browse": {
            "mesh_term": [
                "Spondylitis", 
                "Spondylitis, Ankylosing"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is an open-label, history-controlled, multi-site study of golimumab in participants\n      with AS. For evaluation of the primary study outcome measure, participants will serve as\n      their own control. The period before start of treatment with an anti-tumor necrosis factor\n      (TNF) agent will serve as historical control for the incidence of extra-articular\n      manifestations, with a review of the medical records done for the previous 1-year period.\n\n      Each participant will participate in the study for approximately 12 months from the time the\n      participant signs the Informed Consent Form through the final contact. Two to four weeks\n      before study start, each participant will be receiving study treatment for approximately 12\n      months, depending on the response to golimumab after 3 months. All participants will be\n      followed for a minimum of 12 months, irrespective of the duration of golimumab treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  May not have been treated with golimumab prior to study enrollment\n\n          -  Must be able to provide retrospective data concerning extra-articular manifestations\n             and episodes with a recall period of at least 12 months prior to anti-TNF use\n\n          -  Must have definite AS according to the modified New York criteria in the Netherlands\n\n          -  Must be candidate for treatment with anti-TNF agent according to the\n\n        Assessment of SpondyloArthritis International Society (ASAS) consensus\n\n          -  Must be able to adhere to dose and visit schedules\n\n        Exclusion Criteria:\n\n          -  Any exclusion criteria stated in the Summary of Product Characteristics for golimumab\n\n          -  Use of any investigational biological or chemical agents within 30 days or 2\n             half-lives (whichever is longest) of screening"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 1, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01668004", 
            "org_study_id": "8259-012", 
            "secondary_id": "2012-002458-21"
        }, 
        "intervention": {
            "arm_group_label": "Golimumab 50 mg", 
            "description": "Golimumab 50 mg subcutaneously once monthly.", 
            "intervention_name": "Golimumab", 
            "intervention_type": "Biological", 
            "other_name": "Simponi\u00ae"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 14, 2014", 
        "number_of_arms": "1", 
        "official_title": "Open-Label, Phase 4 Study, Investigating the Incidence of Extra-Articular Manifestations in Subjects With Ankylosing Spondylitis Treated With Golimumab; Protocol No. MK-8259-012", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Netherlands: Ministry of Health, Welfare and Sport", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Annual Incidence Rate of Uveitis Attacks in Participants Before Treatment and After the Start of Treatment with Golimumab", 
            "safety_issue": "No", 
            "time_frame": "Twelve Months Prior to Enrollment to Study Month 12"
        }, 
        "removed_countries": {
            "country": "Netherlands"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01668004"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Annual Incidence Rate of New-Onset or Flares of Inflammatory Bowel Disease (IBD) and Psoriasis in Participants Before Treatment and After the Start of  Treatment With Golimumab", 
                "safety_issue": "No", 
                "time_frame": "Twelve Months Prior to Enrollment to Study Month 12"
            }, 
            {
                "measure": "Mean Change From Baseline in the Bath Ankylosing Spondylitis Disease Activity Index 50 (BASDAI 50) Following Treatment With Golimumab", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Month 3"
            }, 
            {
                "measure": "Mean Change From Baseline in the Ankylosing Spondylitis Disease Activity Score (ASDAS) Following Treatment With Golimumab", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Month 3"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}